Company CVAbout Laurus Labs Ltd 
Laurus Labs Ltd
Mid Cap
Pharmaceuticals & Biotechnology
Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others.
Company Coordinates
Company Details
Plot No 21 Jawaharlal Nehru, Pharma City Parawada Visakhapatnam Andhra Pradesh : 531021
Registrar Details
Karvy Computershare Pvt Ltd., Karvy Selenium, Tower-B Plot No 31 & 32, Survey No 116/22, 115/24, 115/25, Financial District, Nanakramguda, Serilingampally, Mandal Ranga Reddy Dist, Hyderabad
Capital StructureCapital Structure
Present Equity Capital
INR 107.83 Cr
Number of Shares
53.91 Cr
Face Value
INR 2.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
27-May-2024
53.91
107.83
161349
2
Issued under ESOP Scheme
07-Dec-2023
53.9
107.79
314933
2
Issued under ESOP Scheme
16-Dec-2022
53.87
107.73
1291590
2
Issued under ESOP Scheme
19-Dec-2021
53.74
107.47
756950
2
Issued under ESOP Scheme
21-Dec-2020
53.66
107.32
607390
2
Issued under ESOP Scheme
28-Sep-2020
53.6
107.20
428795996
2
Stock Split
15-Jul-2020
10.72
107.20
278500
10
Issued under ESOP Scheme
23-Sep-2019
10.69
106.91
477750
10
Issued under ESOP Scheme
23-Sep-2019
10.69
106.91
477750
10
Issued under ESOP Scheme
19-Sep-2018
10.63
106.28
248250
10
ESOP
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Non Institution
Pledged Promoter Holdings
2.6948
Mutual Funds
Held by 38 Schemes (10.15%)
FIIs
Held by 405 FIIs (28.0%)
Promoter with highest holding
M/s. Nsn Holdings (represented By Its Managing Partner, Dr. Satyanarayana Chava) (22.98%)
Highest Public shareholder
Mirae Asset Large & Midcap Fund (4.33%)
Individual Investors Holdings
20.49%
Board of Directors
Management
Designation
Remuneration
M V G Rao
Chairman & Independent Directo
25.0 lacs
CHAVA SATYANARAYANA
Executive Director & CEO
18.64 cr
VENKATA RAVI KUMAR VANTARAM
Executive Director & CFO
4.97 cr
Aruna Bhinge
Independent Non Exe. Director
26.0 lacs
Rajesh Koshy Chandy
Independent Non Exe. Director
38.59 lacs
Ravindranath Kancherla
Independent Non Exe. Director
24.5 lacs
Venkata Lakshmana Rao Chunduru
Executive Director
3.3 cr
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
Packing Materials
82.67
0%
Packing Materials
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
No Data Available for Finished Goods Segmentation
No Data Available
Stock DNARevenue and Profits:
Net Sales:
2,026 Cr
(Quarterly Results - Jun 2026)
Net Profit:
368 Cr
Pharmaceuticals & Biotechnology
INR 99,631 Cr (Mid Cap)
92.00
37
0.11%
0.45
16.77%
18.72
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
